BRPI0407742A - uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida - Google Patents

uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida

Info

Publication number
BRPI0407742A
BRPI0407742A BRPI0407742-3A BRPI0407742A BRPI0407742A BR PI0407742 A BRPI0407742 A BR PI0407742A BR PI0407742 A BRPI0407742 A BR PI0407742A BR PI0407742 A BRPI0407742 A BR PI0407742A
Authority
BR
Brazil
Prior art keywords
formulation
treatment
well
glucocorticoids
ocular angiogenesis
Prior art date
Application number
BRPI0407742-3A
Other languages
English (en)
Inventor
David P Bingaman
Abbot F Clark
Rajni Jani
Stella M Robertson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0407742A publication Critical patent/BRPI0407742A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"USO DE GLICOCORTICóIDES PARA PREPARAçãO DE FORMULAçõES UTILIZáVEIS NO TRATAMENTO DE ANGIOGêNESE OCULAR PATOLóGICA, BEM COMO FORMULAçãO ASSIM OBTIDA". A presente invenção refere-se a formulações de glicocorticóides sozinhos ou em combinação com acetato de anecortave que são úteis para evitar e tratar angiogênese ocular patológica e edemas associados.
BRPI0407742-3A 2003-02-20 2004-02-05 uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida BRPI0407742A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44894403P 2003-02-20 2003-02-20
PCT/US2004/003515 WO2004073608A2 (en) 2003-02-20 2004-02-05 Formulations of glucocorticoids to treat pathologic ocular angiogenesis

Publications (1)

Publication Number Publication Date
BRPI0407742A true BRPI0407742A (pt) 2006-02-14

Family

ID=32908675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407742-3A BRPI0407742A (pt) 2003-02-20 2004-02-05 uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida

Country Status (16)

Country Link
US (2) US20040167109A1 (pt)
EP (1) EP1594511A2 (pt)
JP (2) JP2006518383A (pt)
KR (1) KR20050102653A (pt)
CN (1) CN100431544C (pt)
AR (1) AR043252A1 (pt)
AU (1) AU2004212900A1 (pt)
BR (1) BRPI0407742A (pt)
CA (1) CA2516790A1 (pt)
MX (1) MXPA05008396A (pt)
PL (1) PL378209A1 (pt)
RU (1) RU2005129278A (pt)
TW (1) TW200507858A (pt)
UY (1) UY28203A1 (pt)
WO (1) WO2004073608A2 (pt)
ZA (1) ZA200505990B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663144A1 (en) * 2003-09-23 2006-06-07 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
EP1931387A4 (en) * 2005-09-07 2012-07-11 Southwest Res Inst BIODEGRADABLE MICROTEILED PHARMACEUTICAL FORMULATIONS WITH IMPROVED RELEASE RATES
US9693967B2 (en) 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
AU2006330501B2 (en) * 2005-12-22 2012-04-05 Alcon Research, Ltd. C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
CN101687042A (zh) * 2007-07-20 2010-03-31 爱尔康公司 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂
WO2011141456A1 (en) * 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
CA2951721C (en) * 2014-06-12 2023-09-26 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
EP1473003B1 (en) * 1999-10-21 2008-11-19 Alcon, Inc. Drug delivery device
ES2240180T3 (es) * 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
MXPA05000773A (es) * 2002-08-05 2005-04-19 Alcon Inc Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad.

Also Published As

Publication number Publication date
AU2004212900A1 (en) 2004-09-02
KR20050102653A (ko) 2005-10-26
MXPA05008396A (es) 2006-03-30
WO2004073608A3 (en) 2005-03-24
ZA200505990B (en) 2006-12-27
EP1594511A2 (en) 2005-11-16
UY28203A1 (es) 2004-08-31
CA2516790A1 (en) 2004-09-02
RU2005129278A (ru) 2006-01-27
TW200507858A (en) 2005-03-01
CN1750829A (zh) 2006-03-22
JP2006518383A (ja) 2006-08-10
US20040167109A1 (en) 2004-08-26
US20060074061A1 (en) 2006-04-06
AR043252A1 (es) 2005-07-20
PL378209A1 (pl) 2006-03-20
CN100431544C (zh) 2008-11-12
WO2004073608A2 (en) 2004-09-02
JP2007056041A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
WO2006116591A3 (en) Ophthalmic formulations comprising prednisolone acetate and tobramycin and uses thereof
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
BR0309855A (pt) Pirazolpiridinas substituìdas com carbamato
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
ECSP067113A (es) Compuestos amido y su uso como farmacéuticos
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
PA8481301A1 (es) Derivados de 4,4-biarilpiperidina
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0312232A (pt) Inibidores de caspases e seus usos
BRPI0518247A2 (pt) composiÇÕes compreendo inibidores de cinases jun n-terminais e uso
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
BRPI0414699A (pt) formulações de acetato de anecortave e acetonida de triancinolona para injeção
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.